In AML, Ten-Eleven Translocation 2 (TET2) mutations have been shown to enhance mTORC1 signaling, linking epigenetic dysregulation to aberrant metabolic reprogramming (92, 93). The gene discussed is TET2; the disease is acute myeloid leukemia.